Aptevo Therapeutics
Seattle, Washington, United States · Healthcare, Health Care
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.
Key facts
- Headquarters
- Seattle, Washington, United States
- Employees
- 37
- Industries
- Healthcare, Health Care
- Status
- Public (APVO)
- Website
- aptevotherapeutics.com
- Company page
Recent activity at Aptevo Therapeutics
- : SEC 8-K (1.01): On November 11, 2026, Aptevo Therapeutics Inc. entered into Warrant Inducement and Reload Letters with certain holders of the Company's existing inducement common stock purchase warrants. The holders agreed to exercise existing warrants for 2,777,778 shares of common stock at a reduced price of $1.08 per share, resulting in gross proceeds of approximately $3.0 million. In return, the Company issued new warrants entitling holders to purchase an additional 13,888,890 shares at the same exercise price. This transaction, which closed on November 12, 2026, may generate additional proceeds of approximately $15.0 million if fully exercised. The net proceeds are intended for working capital and general corporate purposes.
- : SEC 8-K (8.01): On November 9, 2026, Aptevo Therapeutics Inc. announced that it presented new preclinical data from its next-generation multispecific platform on November 7, 2026, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. This event highlights significant advancements in the company's research and development efforts, potentially impacting future therapeutic strategies. The press release detailing this announcement has been included as Exhibit 99.1. The data could provide insights into Aptevo's innovative approaches in immunotherapy, which may influence investor sentiment and bolster the company's market position.
- : SEC 8-K (8.01): On November 5, 2026, Aptevo Therapeutics Inc. announced an important clinical development milestone for its drug mipletamig, highlighting a substantial reduction in infusion-related reactions (IRRs) achieved through successive refinements to its priming-dose regimen. This development represents a significant improvement in patient safety and treatment efficacy, which could enhance the competitive positioning of the drug in the market. The press release indicates the company's ongoing commitment to advancing its clinical programs, with potential positive implications for future regulatory filings and market acceptance.
- : SEC 8-K (8.01): On October 30, 2026, Aptevo Therapeutics Inc. filed a prospectus supplement under its effective registration statement on Form S-3, relating to the offering of shares of common stock valued at up to $2,309,834. This follows an existing At The Market Offering Agreement with Roth Capital Partners, LLC. The Company has already sold 303,157 shares for gross proceeds of $11.8 million. The filing includes a legal opinion from Paul Hastings LLP regarding the shares, emphasizing that this report does not constitute an offer to sell or solicitation for purchasing these securities, adhering to relevant securities laws.
- : SEC 8-K (8.01): On October 26, 2026, Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have successfully advanced to allogeneic stem cell transplant after receiving treatment with mipletamig in combination with venetoclax and azacitidine. This development signifies a noteworthy advancement in treatment options for AML, demonstrating the potential efficacy of the combination therapy. The announcement was made through a press release, highlighting the importance of this milestone for the Company and its strategic focus on improving patient outcomes in this indication.
- : SEC 8-K (1.01): On October 23, 2026, Aptevo Therapeutics Inc. entered into Amendment No. 6 to the Rights Agreement originally dated November 8, 2020, with Broadridge Corporate Issuer Solutions, LLC. This Amendment extends the Final Expiration Date of the Rights Agreement to October 23, 2027, and modifies the Purchase Price for the contingent rights to purchase Preferred Shares to $14.56 each. The strategic implications of this Amendment could affect the rights of shareholders and the overall financial structure of the Company, ensuring better alignment with shareholder interests over the extended timeline.
- : SEC 8-K (8.01): On October 14, 2026, Aptevo Therapeutics Inc. announced via a press release that their multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. This event is scheduled to take place from November 4 to November 8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. This announcement is significant as it highlights the company's ongoing commitment to advancing cancer treatment technologies and increases visibility in the field. The press release attached as Exhibit 99.1 emphasizes the importance of this presentation for the company's strategic objectives.
- : SEC 8-K (8.01): On September 24, 2026, Aptevo Therapeutics Inc. announced in a press release the progress of its next-generation trispecific programs, focusing on optimizing several trispecific candidates for reliable manufacturing, a critical step before human testing. The company plans to initiate Investigational New Drug (IND) enabling studies for its lead candidate, APVO451, in the first half of 2027. This advancement in their product pipeline could have significant implications for future therapeutic applications. The press release represents Aptevo's commitment to moving forward in drug development and is part of broader strategic efforts to advance their innovative therapies.
- : SEC 8-K (5.07): On September 22, 2026, Aptevo Therapeutics Inc. held a Special Meeting of Stockholders where stockholders voted on four proposals. One significant proposal included an amendment to the Company’s Amended and Restated Certificate of Incorporation, which aimed to introduce certain technical and administrative changes; however, this proposal did not receive approval with 654,005 votes in favor, 93,851 against, and 4,759 abstentions. The outcome of this meeting and the specific voting results reflect the decision-making process affecting governance and structure of the Company. The event underscores the involvement of stakeholders in shaping the future direction of the Company amidst the current market conditions.
- : SEC 8-K (8.01): On September 3, 2026, Aptevo Therapeutics Inc. announced a significant clinical achievement in its press release regarding the mipletamig triplet. This treatment demonstrated a 93% clinical benefit rate in evaluable frontline acute myeloid leukemia (AML) patients harboring TP53 mutations, an extremely challenging patient group that has historically experienced poor responses to available therapies. The date of the announcement directly correlates with the filing date, indicating a fresh and impactful development for the company. This milestone may strongly influence investor confidence and company valuation due to its implications for future treatment protocols and market potential in oncology.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Aptevo Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $3.5M |
| Apr 2025 | Seed | $2.1M |
Leadership
- Marvin White, Executive Officer
- Daphne Taylor, Vice President
Verified email and direct lines for Aptevo Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Aptevo Therapeutics files 3 employee benefit plans with the U.S. Department of Labor. The next plan year renews in Dec 2026.
Companies similar to Aptevo Therapeutics
- Korsana Biosciences · Healthcare, Health Care
- LumiThera · Healthcare, Health Care
- NOWDiagnostics, Inc. · Healthcare, Health Care
- Microbot Medical · Healthcare, Health Care
- Redi.Health · Healthcare, Health Care
About Aptevo Therapeutics: questions and answers
What does Aptevo Therapeutics do?
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.
Where is Aptevo Therapeutics headquartered?
Aptevo Therapeutics is headquartered in Seattle, Washington, United States.
How many employees does Aptevo Therapeutics have?
Aptevo Therapeutics has about 37 employees.
Has Aptevo Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Aptevo Therapeutics. The most recent, $3.5M, was in Aug 2026.
Who leads Aptevo Therapeutics?
Daphne Taylor is a Vice President at Aptevo Therapeutics.
What is the latest news on Aptevo Therapeutics?
On Oct 30, 2025, SEC 8-K (1.01): On November 11, 2026, Aptevo Therapeutics Inc. entered into Warrant Inducement and Reload Letters with certain holders of the Company's existing inducement common stock purchase warrants. The holders agreed to exercise existing warrants for 2,777,778 shares of common stock at a reduc
Is Aptevo Therapeutics a public company?
Yes. Aptevo Therapeutics is publicly traded under the ticker APVO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy